Acute nephrotic syndrome: a small trial suggests exercise may help, but findings are inconclusive

Exercise is sometimes avoided during acute nephrotic syndrome for fear of worsening protein loss in the urine or kidney function. A randomized trial involving 27 hospitalized adults suggests a possible benefit for exercise capacity. But the main difference between groups is not statistically significant, and safety remains insufficiently established.

Illustration of exercise capacity assessment in a hospital setting.
TrainingEditorial illustration, not study data.

An early exercise program compared with usual care

This single-center trial involved adults hospitalized for acute nephrotic syndrome and treated with glucocorticoids. The researchers assigned participants to an early exercise group of 13 people or a usual care group of 14 people.

The primary outcome was peak oxygen uptake, or peak VO2, measured at baseline and at six weeks. This measure assesses the capacity to sustain physical exertion. The abstract provided does not detail the program’s content, intensity or frequency.

Improvement in one group is not enough to demonstrate an effect

In the exercise group, peak VO2 increased by 3.45 mL/kg/min, with a 95% confidence interval of 1.22 to 5.67. In the usual care group, the increase was 1.00 mL/kg/min, with an interval ranging from −1.14 to 3.14.

However, the decisive comparison is between groups, not whether there is a statistically significant improvement in just one group. After adjustment, the difference at six weeks was 2.46 mL/kg/min in favor of exercise, but its confidence interval ranged from −0.12 to 5.03. It therefore included no difference. The result suggests a possible benefit without clearly demonstrating it.

No clear signal for non-remission, but safety remains uncertain

The researchers also assessed non-remission at six weeks, defined as proteinuria of at least 0.3 g per day. The relative risk with exercise was 0.673, but the confidence interval, from 0.266 to 1.703, remained compatible with either a decrease or an increase in risk.

The trial therefore does not show an increase in non-remission. That does not, however, prove the program is safe. The abstract provides neither detailed kidney function results nor a summary of adverse events that would allow conclusions about overall safety.

Limitations to keep in mind

The sample is limited to 27 participants at a single center, with assessment at six weeks. Only the PubMed abstract was consulted, not the full text. The exercise program, adverse events, funding and conflicts of interest could not be verified.

What we can take away

This trial provides an encouraging signal for early exercise in a specific hospital setting. It is not enough to establish its effectiveness or justify a self-directed program for people with acute nephrotic syndrome.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.